|
|
|
 |
La Réforme 2011 du Médicament
|
|
Quelles implications pour votre modèle commercial et votre structure organisationnelle ?
Par Lionel Delaporte, Stéphane Parnis, Bastien Roux et Anne Sophie Demange.
Septembre 2011. |
|
Planning for Uncertainty
|
|
"Future treatment dynamics in NHL & Implications for strategic planning"
By Dr Rachel Laing, Olivier Lesueur & Carter Gould.
May 2011. |
|
Etude LEEM Biomarqueurs
|
|
"Le biomarqueur comme outil de diagnostic compagnon de produits thérapeutiques.
Impacts sur la R&D et sur les modèles économiques des industriels de la Santé"
Etude réalisée pour le compte du LEEM.
Février 2011. |
|
"The Big Buy"
|
|
EBR, Spring 2009.
« Alain J Gilbert and Meredith Edwards of Bionest Partners examine trends for biotech partnering in 2009 and discuss how to optimise outcomes in these turbulent conditions ». |
|
"Pharmaceutical Executive"
|
|
The Business Magazine of Pharma. Vol 28, Number 11, November 2008.
« Real innovation is the name of the game—products and technologies that specifically meet a previously unmet medical need, and therefore unequivocally attract needed funding. Market access and maintenance are knowledgebased, cross-functional processes, which leading pharma companies must implement immediately ». |
|
"Minimums"
|
|
Financial Advisory Newsletter
Q3 - 2008. |
|
"Stratégies pour
l’innovation pharmaceutique"
|
|
Expertise Pharmacie, Octobre 2008
« Et si la crise actuelle avait finalement des conséquences positives pour les laboratoires et leur potentiel d'innovation ? »
Claude Allary, directeur général de Bionest Consultants, et Julian Ozdowski, senior consultant, s'attachent à analyser les transformations profondes de l'innovation pharmaceutique, notamment grâce à des accords de portée considérable avec les entreprises de biotechnologie. |
|
"Influenza: the Avoidable Killer"
|
|
SCRIP Drug Market developments, July 2008
Influenza is a disease of global health significance against which the fight is far from over.
By Claude Allary & Dr Meredith Edwards |
|
"Roadmap for success in oncology"
|
|
SCRIP Executive Briefing, Vol 1 No 3, 2008
The worldwide oncology market is projected to outgrow the rest of the pharma industry, becoming the number one therapeutic class in revenue terms by 2011. So will oncology become pharma’s new “holy grail”?
By Dr Frederic Desdouits, Lionel Delaporte and Dr Stéphane Parnis |
|
"Pharma Deals"
|
|
Pharmaceutical Executive, may 2008
Many say licensing is the new R&D. The thrid quarter of 2007 featured some pricey cherry-picking. Will the unions bear fruit? We've the intersting ones to watch.
By Daniel Teper |
|
"Up or Out in Oncology" Executive Summary only
|
|
Bionest Disease Area Review, November 2007
Stéphane Parnis, Guillaume Madec, Lionel Delaporte and Frédéric Desdouits produced the second edition of our annual review related to the outlook of the oncology market. As part of the report, the authors provide advice to bio-pharmaceutical companies on how to develop and sustain a profitable business in this attractive but risky domain.
To request the 78-page full report, please click here |
|
Net Profit
|
|
EBR, autumn 2007
Bionest¹s Frédéric Desdouits and Catherine Pichereau compare methods of valuing biotech and find that public markets offer a means to value companies even with as little information as is available on their website. |
|
Vaccines : Growth Boosters
|
|
Exane BNP Paribas Equity Research Report, June 2006
Alain Gilbert, Claude Allary and Frédéric Desdouits, in collaboration with
Exane BNP Paribas, anticipate the radical changes set to occur in the
vaccines industry and illustrate them with two case studies |
|
Reaching Maturity – New Challenges for an Evolving Industry
|
|
VentureCapital Magazin, April 2006 (article in German)
Frédéric Desdouits and Christian Hein analyse the current state of the German biotech industry and its future challenges: the need to internationalize and to start commercializing its own products. |
|
Oncology Pipelines – Searching is not Finding
|
|
Exane BNP Paribas Equity Research Report, March 2006
Frédéric Desdouits and Stéphane Parnis, in collaboration with Exane BNP Paribas, have produced an in-depth study of the oncology sector, reviewing the past and forecasting future trends. |
|
The European Giant Stirs from Slumber
|
|
Biotechnologies et Finances, December 2005
Frédéric Desdouits and Catherine Pichereau review the evolution of the financial landscape of the Biotech industry in 2005. |
|
Great Oaks from Little Acorns
|
|
Scrip Magazine, November 2005
Alain Gilbert, Mark Larkin, Vanessa Coudre and Xavier Paoli explain how big things can come from small beginnings with an EAP (Early Access Programme). |
|
Risky Business
|
|
Scrip Magazine, September 2004
Alain Gilbert and Mark Larkin discuss how European Biotech companies can be sustainable in a risk-averse environment. |
|
EU biotech: United we Stand, Divided we Fall
|
|
Scrip Magazine, July/August 2004
Claude Allary and Catherine Pichereau look at the results of a survey examining why there are so few biotech consolidations in Europe, and suggest ways to increase their number. |
|
|
